CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

Orchestra BioMed slips premarket after $75 mln share offering

By Reuters News

** Shares of Orchestra BioMed Holdings OBIO.O down 2.3% at $5.49 before the bell on Fri after $75 mln follow-on priced

** New Hope, Pennsylvania-based OBIO late Thurs announced 15 mln shares at $5, an 11% discount to last sale

** Piper Sandler and TD Cowen joint bookrunners, joined by BTIG

** Co intends to use net offering proceeds to fund its atrioventricular interval modulation (AVIM) therapy for treatment of hypertension, and its Virtue Sirolimus AngioInfusion Balloon (SAB) for treatment of atherosclerotic artery disease

** As of Nov 4, co has ~61.45 mln shares outstanding, per the prospectus

** OBIO shares finished down ~6% on Thurs, trimming gain over the past three months to 35%

** All 7 analysts covering the stock are bullish; median PT $11, per LSEG

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk